HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Export rule enforcement

This article was originally published in The Rose Sheet

Executive Summary

As it considers changes to the reg, FDA will continue to "exercise enforcement discretion" on requirement in its export notification and recordkeeping rule that records for exported cosmetics or foods be made available to the agency for inspection. Also suspended is mandate that marketers of all regulated products prepare a notarized certification that an exported product does not conflict with the laws of the importing country. Enforcement of two provisions earlier was postponed until July 19 in response to a joint request by CTFA and the Grocery Manufacturers of America (1"The Rose Sheet" July 1, 2002, p. 8). In a July 22 letter to the groups' outside counsel, Peter Barton Hutt (Covington & Burling), FDA said it may issue an advanced notice of proposed rulemaking to seek public comment...

You may also be interested in...



Export Rule Records Inspection Enforcement For Cosmetics Suspended – FDA

FDA will temporarily refrain from enforcing the provision of its export notification and recordkeeping rule that requires companies to make records for cosmetics or foods exported under the law available to the agency during an inspection

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel